Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 8/20 | 0.52 |
| ▸ | PPARA | Q07869 | 8/20 | 0.52 |
| ▸ | PPARG | P37231 | 7/20 | 0.52 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | KMO | O15229 | 8/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1034666 | 0.92 | PPARG (0.54) | PPARDPPARAPPARGPTGDR2KMO | |
| SCHEMBL1034083 | 0.89 | PPARA (0.49) | PPARDPPARAPPARGPTGDR2KMO | |
| SCHEMBL1030729 | 0.87 | PPARD (0.54) | PPARDPPARAPPARGPTGDR2 | |
| SCHEMBL1031691 | 0.85 | PPARD (0.51) | PPARDPPARAPPARGKMO | |
| SCHEMBL1673112 | 0.84 | PPARA (0.49) | PPARDPPARAPPARGKMO | |
| SCHEMBL24742455 | 0.83 | PPARD (0.52) | PPARDPPARAPPARGKMO | |
| SCHEMBL30002914 | 0.83 | PPARD (0.52) | PPARDPPARAPPARGKMO | |
| SCHEMBL4803438 | 0.82 | PPARD (0.77) | PPARDPPARAPPARG | |
| SCHEMBL1033114 | 0.82 | PPARG (0.47) | PPARDPPARAPPARG | |
| SCHEMBL1032975 | 0.82 | PPARD (0.48) | PPARDPPARAPPARGPTGDR2KMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011020001-A9 | USE OF PPAR DELTA LIGANDS FOR THE TREATMENT OR PREVENTION OF INFLAMMATION OR ENERGY METABOLISM/PRODUCTION RELATED DISEASES | CERENIS THERAPEUTICS S.A. (FR) | 2011-05-26 | — | — | WO | disclosed |
| US-20110092517-A1 | Use of PPAR Delta Ligands for the Treatment or Prevention of Inflammation or Energy Metabolism/Production Related Diseases | Cerenis Therapeutics S.A. & Nippon Chemiphar Co., Ltd. | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092517-A1 | Use of PPAR Delta Ligands for the Treatment or Prevention of Inflammation or Energy Metabolism/Production Related Diseases | PPARD, PPARG, PPARA | PPARD 1/4885PPARA 3/4885PPARG 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.